Opella launches as independent company following Sanofi divestiture
Opella has officially launched as a standalone company after Sanofi sold a majority stake to investment firm CD&R. The company will focus on expanding its presence in the global self-care market.
Opella has officially begun operations as an independent entity after completing its separation from Sanofi. Investment firm CD&R acquired a 50% controlling stake in the company, with Sanofi retaining a significant minority shareholding. This marks a new chapter for Opella in the global self-care market.
The company operates within the over-the-counter (OTC) and Vitamins, Minerals, and Supplements (VMS) sector, a market valued at approximately €190 billion. Opella aims to simplify health management for consumers, addressing growing demands driven by an aging population and increased digital access to healthcare solutions.
Led by President and CEO Julie Van Ongevalle, Opella boasts a portfolio of 100 brands, including well-known names such as Allegra, Dulcolax, and Doliprane. David Taylor, former Chairman and CEO of Procter & Gamble, has been appointed Chairman of the Supervisory Board. The company plans to strengthen its existing brands and pursue growth through strategic acquisitions and geographic expansion.